Acquired dyschromatopsia in acute myelocytic leukaemia.
BACKGROUND
Patients with haematological malignancy are referred to the ophthalmologist either with visual symptoms or to exclude orbital or intraocular involvement after the diagnosis has been established. This report describes a patient with acute myelocytic leukaemia (AML) whose presenting symptom was dyschromatopsia.


METHODS
A 52-year-old female, previously in good health, presented with a disturbance of colour vision. On examination, there was bilateral reduction in visual acuity, impaired colour vision and severely constricted visual fields. Electrophysiological testing and colour contrast sensitivity (CCS) assessment were performed.


RESULTS
CCS showed bilateral threshold elevation in the tritan axis of both eyes, right worse than left. Pattern ERG showed marked macular dysfunction in the right eye, but was normal in the left eye. Full-field ERGs fell within the normal range. Pattern VEPs were reduced in the right eye, without peak time shift; flash VEPs showed bilateral delay. Investigation showed severe anaemia, and a bone marrow biopsy confirmed a diagnosis of acute AML. There was symptomatic improvement in visual acuity and colour vision following blood transfusion and initiation of chemotherapy.


CONCLUSIONS
This appears to be the first case report of dyschromatopsia in AML with symptomatic improvement following treatment. The case lends support to previously suggested hypotheses of chromatic visual disturbance in association with presumed hypoxia.
Eye Department, University College London Hospital, Third Floor, Central Wing, 250 Euston Road, London, NW1 2PQ, UK, mahdi207@yahoo.com.
Mohammed
M
Ziaei
Graham E
GE
Holder
Mostafa A
MA
Elgohary
Fion D
FD
Bremner
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003119:Color Perception Tests; D055253:Color Vision / Q000502:physiology; D003117:Color Vision Defects / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D015350:Contrast Sensitivity / Q000502:physiology; D017707:Erythrocyte Transfusion; D005074:Evoked Potentials, Visual / Q000502:physiology; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D019572:Retinal Neoplasms / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology
D000970:Antineoplastic Agents